Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$15.19
$8.13
$19.08
$24.33M0.4123,208 shs237,144 shs
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
$2.40
-3.2%
$3.10
$1.80
$7.93
$104.83M0.17264,306 shs207,059 shs
IO Biotech, Inc. stock logo
IOBT
IO Biotech
$1.43
-4.0%
$1.27
$0.66
$1.73
$94.21M0.36283,908 shs209,959 shs
OptiNose, Inc. stock logo
OPTN
OptiNose
$9.60
$9.55
$4.82
$19.50
$97.22M-0.8862,916 shsN/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00%0.00%0.00%+12.00%+55.66%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.00%+11.26%-12.10%-32.14%+246,999,900.00%
IO Biotech, Inc. stock logo
IOBT
IO Biotech
0.00%+4.51%-5.94%+65.38%+25.42%
OptiNose, Inc. stock logo
OPTN
OptiNose
0.00%0.00%0.00%+5.49%-38.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.3412 of 5 stars
0.00.00.04.20.60.80.0
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
1.227 of 5 stars
3.70.00.00.00.90.00.0
IO Biotech, Inc. stock logo
IOBT
IO Biotech
2.6363 of 5 stars
3.73.00.00.00.62.50.6
OptiNose, Inc. stock logo
OPTN
OptiNose
0.7278 of 5 stars
1.00.00.04.20.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00
N/AN/AN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
3.40
Buy$12.67427.78% Upside
IO Biotech, Inc. stock logo
IOBT
IO Biotech
3.33
Buy$9.33552.68% Upside
OptiNose, Inc. stock logo
OPTN
OptiNose
2.00
Hold$9.00-6.25% Downside

Current Analyst Ratings Breakdown

Latest CARA, OPTN, HURA, and IOBT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/19/2025
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$9.00 ➝ $9.00
5/16/2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
5/14/2025
IO Biotech, Inc. stock logo
IOBT
IO Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$7.14M0.00N/AN/A$12.58 per share0.00
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/A$0.34 per shareN/A
IO Biotech, Inc. stock logo
IOBT
IO Biotech
N/AN/AN/AN/A$0.71 per shareN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
$81.86M1.19N/AN/A($11.56) per share-0.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$21.68MN/A0.00N/AN/A291.69%122.09%N/A
IO Biotech, Inc. stock logo
IOBT
IO Biotech
-$95.49M-$1.49N/AN/AN/AN/A-162.55%-125.08%8/12/2025 (Estimated)
OptiNose, Inc. stock logo
OPTN
OptiNose
-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%8/6/2025 (Estimated)

Latest CARA, OPTN, HURA, and IOBT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$0.13-$0.15-$0.02-$0.15N/AN/A
5/13/2025Q1 2025
OptiNose, Inc. stock logo
OPTN
OptiNose
-$0.74-$1.01-$0.27-$1.92$17.70 million$18.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/AN/AN/AN/AN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/AN/A
IO Biotech, Inc. stock logo
IOBT
IO Biotech
N/AN/AN/AN/AN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/A
4.77
4.71
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A
3.00
3.00
IO Biotech, Inc. stock logo
IOBT
IO Biotech
N/A
2.32
2.32
OptiNose, Inc. stock logo
OPTN
OptiNose
N/A
0.79
0.72

Institutional Ownership

CompanyInstitutional Ownership
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
44.66%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.62%
IO Biotech, Inc. stock logo
IOBT
IO Biotech
54.76%
OptiNose, Inc. stock logo
OPTN
OptiNose
85.60%

Insider Ownership

CompanyInsider Ownership
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
3.10%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.20%
IO Biotech, Inc. stock logo
IOBT
IO Biotech
2.30%
OptiNose, Inc. stock logo
OPTN
OptiNose
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
804.57 million4.43 millionOptionable
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A43.68 million43.59 millionN/A
IO Biotech, Inc. stock logo
IOBT
IO Biotech
3065.88 million64.37 millionNot Optionable
OptiNose, Inc. stock logo
OPTN
OptiNose
19010.13 million9.83 millionNot Optionable

Recent News About These Companies

Optinose reports Q4 EPS (3c) vs ($1.33) last year
Optinose downgraded to Neutral from Buy at H.C. Wainwright
Optinose downgraded to Neutral from Overweight at Piper Sandler
Optinose downgraded to Hold from Buy at Lake Street
Lake Street Downgrades OptiNose (OPTN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cara Therapeutics stock logo

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

TuHURA Biosciences stock logo

TuHURA Biosciences NASDAQ:HURA

$2.40 -0.08 (-3.23%)
Closing price 04:00 PM Eastern
Extended Trading
$2.40 0.00 (0.00%)
As of 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

IO Biotech stock logo

IO Biotech NASDAQ:IOBT

$1.43 -0.06 (-4.03%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 -0.06 (-4.55%)
As of 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

OptiNose stock logo

OptiNose NASDAQ:OPTN

$9.60 0.00 (0.00%)
As of 05/21/2025

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.